The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells
Kato, M, Paranjape, T, Ullrich, R, Nallur, S, Gillespie, E, Keane, K, Esquela-Kerscher, A, Weidhaas, J B, Slack, F J
Published in Oncogene (25.06.2009)
Published in Oncogene (25.06.2009)
Get full text
Journal Article
Regression of murine lung tumors by the let-7 microRNA
Trang, P, Medina, P P, Wiggins, J F, Ruffino, L, Kelnar, K, Omotola, M, Homer, R, Brown, D, Bader, A G, Weidhaas, J B, Slack, F J
Published in Oncogene (18.03.2010)
Published in Oncogene (18.03.2010)
Get full text
Journal Article
cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation
Metheetrairut, C, Adams, B D, Nallur, S, Weidhaas, J B, Slack, F J
Published in Oncogene (26.01.2017)
Published in Oncogene (26.01.2017)
Get full text
Journal Article
Targeted resequencing of the microRNAome and 3′UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer
Chen, X, Paranjape, T, Stahlhut, C, McVeigh, T, Keane, F, Nallur, S, Miller, N, Kerin, M, Deng, Y, Yao, X, Zhao, H, Weidhaas, J B, Slack, F J
Published in Oncogene (16.04.2015)
Published in Oncogene (16.04.2015)
Get full text
Journal Article
A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Chung, C.H., Lee, J.W., Slebos, R.J., Howard, J.D., Perez, J., Kang, H., Fertig, E.J., Considine, M., Gilbert, J., Murphy, B.A., Nallur, S., Paranjape, T., Jordan, R.C., Garcia, J., Burtness, B., Forastiere, A.A., Weidhaas, J.B.
Published in Annals of oncology (01.11.2014)
Published in Annals of oncology (01.11.2014)
Get full text
Journal Article
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
Ratner, E S, Keane, F K, Lindner, R, Tassi, R A, Paranjape, T, Glasgow, M, Nallur, S, Deng, Y, Lu, L, Steele, L, Sand, S, Muller, R-U, Bignotti, E, Bellone, S, Boeke, M, Yao, X, Pecorelli, S, Ravaggi, A, Katsaros, D, Zelterman, D, Cristea, M C, Yu, H, Rutherford, T J, Weitzel, J N, Neuhausen, S L, Schwartz, P E, Slack, F J, Santin, A D, Weidhaas, J B
Published in Oncogene (18.10.2012)
Published in Oncogene (18.10.2012)
Get full text
Journal Article
A Variant in a MicroRNA complementary site in the 3′ UTR of the KIT oncogene increases risk of acral melanoma
Godshalk, S E, Paranjape, T, Nallur, S, Speed, W, Chan, E, Molinaro, A M, Bacchiocchi, A, Hoyt, K, Tworkoski, K, Stern, D F, Sznol, M, Ariyan, S, Lazova, R, Halaban, R, Kidd, K K, Weidhaas, J B, Slack, F J
Published in Oncogene (31.03.2011)
Published in Oncogene (31.03.2011)
Get full text
Journal Article
Ovarian versus uterine serous carcinomas: Clinicopathologic and miRNA analysis
Ahmad, S, Weidhaas, J, Hui, P, Santin, A, Azodi, M, Silasi, D, Schwartz, P, Rutherford, T, Ratner, E
Published in Gynecologic oncology (01.07.2013)
Published in Gynecologic oncology (01.07.2013)
Get full text
Journal Article
Investigating the association of rs2910164 with cancer predisposition in an Irish cohort
McVeigh, T P, Mulligan, R J, McVeigh, U M, Owens, P W, Miller, N, Bell, M, Sebag, F, Guerin, C, Quill, D S, Weidhaas, J B, Kerin, M J, Lowery, A J
Published in Endocrine Connections (01.11.2017)
Published in Endocrine Connections (01.11.2017)
Get full text
Journal Article
RTOG 0116 and 0128: Secondary analysis of ribonucleotide reductase in cervix cancer
Kunos, C, Winter, K, Dicker, A, Small, W, Abdul-Karim, F, Dawson, D, Jhingran, A, Valicenti, R, Weidhaas, J, Gaffney, D
Published in Gynecologic oncology (01.03.2012)
Published in Gynecologic oncology (01.03.2012)
Get full text
Journal Article
RETRACTED: A 3’ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer
Ratner, E, Keane, F, Yu, H, Zelterman, D, Rutherford, T, Santin, A, Schwartz, P, Slack, F, Levine, D, Weidhaas, J
Published in Gynecologic oncology (01.03.2011)
Published in Gynecologic oncology (01.03.2011)
Get full text
Journal Article
Retraction to “A 3′ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer” [Gynecol. Oncol. 120 (2011) S3]
Ratner, E, Keane, F, Yu, H, Zelterman, D, Rutherford, T, Santin, A, Schwartz, P, Slack, F, Levine, D, Weidhaas, J
Published in Gynecologic oncology (2011)
Published in Gynecologic oncology (2011)
Get full text
Journal Article